Zimmer Biomet CEO Moves to 3M
Bryan C. Hanson, the CEO and President of medical device giant Zimmer Biomet for the past six years, is leaving his post and taking up the helm as Chief Executive of 3M’s healthcare business. He is set to become CEO of the Health Care Business Group once it is split off into its own company from the 3M conglomerate in the next year.
“We are pleased to have Bryan join us to successfully complete the spin off of our Health Care business and build a leading independent medical technology innovation company,” said Mike Roman, 3M Chairman and Chief Executive Officer. “His industry expertise, ability to drive growth, and track record of building a strong culture and teams will make an immediate impact.”
An industry veteran, Hanson is trusted to lead 3M’s Health Care Business Group with its deep and diverse portfolio of trusted brands, global capabilities, and leadership in market segments such as wound care, oral care, healthcare IT, and biopharma filtration.
Editas Medicine Names New Chief Scientific Officer
Industry veteran Linda C. Burkly, PhD has been named the new Executive Vice President and Chief Scientific Officer of Editas Medicine, the clinical-stage genome editing company. With more than 35 years of leadership experience in biotech, Dr. Burkly is now charged with leading Editas’ drug discovery team and all activities related to the company’s pipeline of experimental medicines across all therapeutic areas and indications. She brings a track record of contributing to approved medicines and late-stage clinical candidates that include Trogarzo and Tysabri. Prior to joining Editas, Dr. Burkly held positions of increasing responsibility over a 37-year tenure at Biogen.
Gilmore O’Neill, MB, MMSc, President and Chief Executive Officer, Editas Medicine, stated: “Linda’s deep scientific knowledge and her translational abilities make her an ideal leader for our drug discovery team and partner to our clinical organization, enabling us to strategically develop and advance our pipeline to the clinic.”
AbelsonTaylor Group
Janet Barker-Evans has joined the leading communications agency as Executive Vice President, Chief Creative Officer. She will continue to build the company’s creative vision by developing and retaining top creative talent, and partnering with other AbelsonTaylor Group leaders and teams to deliver measurable business success for clients, the core tenet of the company’s “Return on Imagination” philosophy.
Also joining AbelsonTaylor is James Hesdon as Director of Performance Media. Joining the team from Evoke Philadelphia where he served as SVP and Media Director, Hesdon will be responsible for growing and developing the agency’s performance media activation team, overseeing the purchase of programmatic media across brands, and creating successful digital media strategies for clients.
Bayer
Juergen Eckhardt MD, MBA was appointed as the new Head of Business Development & Licensing/Open Innovation of Bayer’s Pharmaceuticals Division. Dr. Eckhardt will continue his prior role in leading Leaps by Bayer, the company’s impact investment arm in breakthrough technologies for healthcare and agriculture.
Boundless Life
The comprehensive healthcare agency focused on breaking through the barriers of launching new therapies has announced its first General Manager of Client Excellence, Lauret Geosits. Geosits has years of managerial experience from her roles at Grey Healthcare Group, FCB Health, and Real Chemistry. She will be responsible for working across the agency to operationalize its vision and lead the development of training, education, and coaching to achieve client excellence.
Cancer Research Institute
Fern Lazar, FINN Partners’ Managing Partner and Global Health Practice Leader, was unanimously elected to the Cancer Research Institute’s Board of Trustees. Lazar is a creative strategist who has spent over 30 years advising leaders on the broadest range of investor, corporate, and product issues in health. She will help guide the Institute to fuel the discovery and development of powerful immunotherapies for all cancers.
Fishawack Health
Veteran marketing executive Celine Vita has joined the global commercialization partner as its new Chief Growth Officer. Vita will be charged with expanding the portfolio of the business by leveraging Fishawack’s capabilities to engage clients seeking innovative commercialization solutions from advisory to implementation and across the product lifecycle from preclinical to post-launch.
imre
Jennifer Richman is bringing a fresh perspective to imre as its new Executive Vice President of Client Operations. Joining from McCann Health New York, Richman will be helping to amplify, grow, and scale the Operations department as the agency continues its forward momentum, taking on more healthcare client work.
JUICE Pharma Worldwide
Industry veteran Jay Carter has been appointed EVP, Business Development of the global creative agency. Carter will be responsible for continuing to expand JUICE’s current client base by highlighting its proven track record of industry firsts in accelerating growth for their clients’ business. Carter’s previous position in his 35-year career was EVP, Director of Business Development at AbelsonTaylor.
Ocular Sciences
The California-based biotech named Frank Allen, PMP as VP of Operations to oversee the operational expansion of Ocular Science and OSRX, an affiliated ophthalmic compounding pharmacy based in Missoula, MT. Allen has gained problem-solving skills from working at leading organizations such as Anheuser Busch and the Spoetzl Brewery.
Pfizer
Chris Boshoff, MD, PhD was promoted to the Pfizer Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President. He is now accountable for the entire oncology pipeline from discovery to early and late-phase clinical development. Dr. Boshoff previously oversaw Pfizer’s Oncology portfolio, including 24 approved innovative cancer medicines and biosimilars in more than 30 indications.
Trinity Life Sciences
A leader in global life sciences commercialization solutions, Trinity Life Sciences promoted its previous President and Chief Commercial Officer, Leslie Orne to be the new CEO. In her 20+ years of leadership experience consulting in the life sciences industry, Orne has overseen the delivery of integrated consulting, insights, and analytics services to Trinity’s 300+ clients and supported billions of dollars in strategic transactions with launches of dozens of products.
VMLY&R Health
Natxo Díaz was appointed the agency’s inaugural Global Head of Health Craft. Previously Chief Creative Officer for VMLY&R Health Spain, Diaz and his team helped VMLY&R Health become the #1 ranked health agency in Spain and #2 in advertising overall. Now, he will drive the agency’s vision to create human-centered campaigns for health and to promote the cross fertilization of ideas from outside health into health campaigns.
